Webinar Date/Time: Tuesday, August 13th, 2024 at 11am EDT|8am PDT|4pm BST|5pm CEST
When sponsors invest in best-of-breed solutions that leverage intelligent integration and workflow automation, it is possible to support a positive technology experience for sites and optimize the clinical supply chain. In this webinar, IQVIA patient technology experts will dive into the flexibility you have when deciding what approach to take when implementing patient technology into your next trial.
Register Free: https://www.appliedclinicaltrialsonline.com/act/patient-technology
Event overview
To improve data quality, reduce site effort, optimize workflows in your clinical trials, and address problems at hand, you need the right technology at the right time. While an integrated platform approach might be best to tackle your goals, you may, instead, only need one or two point products.
When sponsors invest in best-of-breed solutions that leverage intelligent integration and workflow automation, it is possible to support a positive technology experience for sites and optimize the clinical supply chain.
In this webinar, IQVIA patient technology experts will dive into the flexibility you have when deciding what approach to take when implementing patient technology into your next trial.
Three key take-aways
Who Should Attend
Speakers:
Anthony Mikulaschek
Vice President, Commercialization, IQVIA Patient Suite
IQVIA
As the vice president of commercialization for the Patient Suite at IQVIA, Anthony Mikulaschek is responsible for the commercialization of IQVIA's eCOA, eConsent, and IRT platforms. This includes pricing and sales strategies, opportunity configuration, market needs review, IQVIA technology market placement, and strategy. Anthony has extensive experience in validated system configuration, implementation, systems integration, business process reengineering, IT operations, and consulting. He has successfully led the development, delivery, and management of technology solutions for over 37 years. This includes 29 years of experience in the pharmaceutical sector.
Kevin Landells
Vice President, Delivery, IQVIA Patient Suite
IQVIA
Kevin has over 25 years of experience in the IRT/ RTSM industry, having worked across many technical and project management leadership roles. Experienced with developing and leading global teams that deliver managed services spanning operations, project management, client partnerships, and business transformation, Kevin is passionate about improving healthcare and utilizing technology that makes a real difference to patients’ lives. Kevin holds a bachelor’s degree in computer science from Hertfordshire University.
Register Free: https://www.appliedclinicaltrialsonline.com/act/patient-technology
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
2025 DIA Annual Meeting: Why AI and Automation Are Set to Become the New Normal in Clinical Research
June 20th 2025Peter Ronco, CEO, Emmes, shares his long-term vision for artificial intelligence in clinical research, from making automation routine to improving drug discovery, transforming regulatory oversight, reducing animal testing, and promoting ethical, equitable data use worldwide.
FDA to Launch National Priority Voucher Program to Speed Drug Reviews for Critical Therapies
June 18th 2025Under the new initiative, companies may receive a voucher enabling FDA review to be shortened from the standard 10–12 months to just 1–2 months following final application submission if the drug addresses US national health priorities.